Meta-analysis finds systemic lupus erythematosus elevates coronary artery disease risk

This is a meta-analysis synthesizing data from PubMed, Web of Science, Embase, and the Cochrane Library. The study population comprised 2,517,781 individuals from European and East Asian populations. The intervention or exposure was a diagnosis of systemic lupus erythematosus (SLE). The comparator was a general or healthy population. The primary outcome was the risk of developing coronary artery disease (CAD).

The main results showed an elevated risk of CAD in the total population, with a relative risk (RR) of 2.355 (95% CI: 1.924-2.883). In the European population, the RR was 2.028 (95% CI: 1.310-3.138). In the East Asian population, the RR was 2.628 (95% CI: 1.698-4.067). A North American population analysis also showed a higher risk, with an RR of 2.711 (95% CI: 2.379-3.089). A Mendelian randomization analysis using the inverse-variance weighted method did not identify a genetically predicted causal relationship between SLE and CAD, with all P values greater than .05.

The review did not report specific secondary outcomes, safety data, adverse event rates, serious adverse events, discontinuations, or tolerability findings. The study did not report a follow-up period.

These results can be compared to prior landmark studies in this therapeutic area. The current meta-analysis provides a large pooled sample size to quantify the association. However, the Mendelian randomization analysis suggests the observed epidemiological association may not be directly causal, which is a key distinction from some prior observational reports.

Key methodological limitations include the lack of genetic evidence for a direct causal relationship between SLE and CAD, as noted by the authors. The analysis is observational in nature, and causality cannot be inferred from the association findings. The study did not report on potential confounding factors or specific study designs of the included literature.

The clinical implications are that clinicians should remain vigilant and take proactive measures in monitoring CAD among SLE patients, considering the possible indirect effects of SLE on CAD risk. This association warrants attention in clinical practice, but the lack of a genetically supported causal link suggests other factors may be involved.

Key questions remain unanswered. The specific mechanisms linking SLE to CAD risk are not defined. The impact of SLE treatment on CAD risk is not reported. The role of disease duration, activity, or specific autoantibodies in modulating this risk is not detailed. Future research should aim to clarify these indirect pathways.